▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Sean Williams

TMFUltraLong

@AMCScam

Sean Williams is a data-driven Motley Fool contributing analyst who's been investing for 26 years and has penned north of 15,000 articles. You'll find him at the intersection of politics and investing tackling macroeconomic topics of interest (Social Security and Donald Trump's economic/tax policies), analyzing which stocks billionaire investors (e.g., Warren Buffett) are buying and selling, and digging into how the world's most-influential businesses and trends -- everything from the evolution of artificial intelligence (AI) to the next stock split -- are changing Wall Street. He holds a B.A. in Economics from the University of California, San Diego.

Recent Articles by Sean Williams

Feb 15, 2015 by Sean Williams

In Case You Missed It, This New Study is Terrifying for Smokers

A fresh study released this past week adds to smokers' already long list of risk factors associated with tobacco.

Feb 15, 2015 by Sean Williams

Could This New Marijuana Study Smoke Pessimists?

Perceptions about marijuana are changing rapidly, which makes this recent study all the more important for researchers and drug developers utilizing medical marijuana and cannabinoids.

Feb 15, 2015 by Sean Williams

Forget Traditional Chemotherapy! Could 3D Vaccines Eventually Cure Cancer?

Utilizing the body's immune system to help fight cancer is among the latest techniques researchers are using. However, this team of researchers has developed a truly unique new way of combating cancer.

Feb 15, 2015 by Sean Williams

Could the Solution to Treating Alzheimer's Disease Really Be This Simple?

Drug developers have struggled mightily in their attempts to slow Alzheimer's progression, but researchers may have discovered a simple pathway that could lead to new life-improving Alzheimer's drugs.

Feb 15, 2017 by Sean Williams

Can You Guess What Percentage of Americans Think It's OK to Cheat on Their Taxes?

Nearly all taxpayers believe it's every American's duty to pay their share of taxes, yet according to this latest IRS Oversight Board survey, there may be more tax cheaters than you suspect.

Feb 14, 2015 by Sean Williams

In Case You Missed It, There's a New Fastest Growing Drug in the World

For the third time in four years we have a new fastest growing drug of all-time. Find out what drug unseated previous champion Sovaldi for the top honor.

Feb 14, 2015 by Sean Williams

Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer

Did researchers really uncover the mechanism behind intestinal cancer formation? Find out what game-changing news this latest study brings to light and how this could help drug developers plan their attack against intestinal cancers.

Feb 14, 2015 by Sean Williams

Will This Obamacare Line-in-the-Sand Tactic Actually Work?

As Obamacare's open enrollment period for 2015 draws to a close, will this line-in-the-sand tactic designed to boost enrollment actually work?

Feb 13, 2015 by Sean Williams

NVIDIA Corporation Processes 6 Price Target Increases, but Do These Compute?

Following a better-than-expected fourth-quarter report, NVIDIA shares blasted to a new 52-week high on the coattails of six price target hikes. The question is, do these price targets make any sense?

Feb 13, 2015 by Sean Williams

Whole Foods Market, Inc. Lands 3 Price Target Increases: Is It Still a Tasty Buy?

Whole Foods Market cashes in on an outstanding first-quarter earnings report with three price target increases. Are these analysts' increased targets warranted?

Feb 13, 2015 by Sean Williams

1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Reports

Tired of reading through mile-long earnings reports? Have a gander at the one sentence in each of these 10 big pharma earnings reports that tells you everything you need to know about these companies.

Feb 12, 2015 by Sean Williams

Is Yelp Inc. Really Worthy of This Upgrade?

Following the roughest week in more than three years for Yelp stock, the online guide that connects consumers and businesses catches a much needed upgrade. Find out what has one firm excited and what that means for investors.

Feb 12, 2015 by Sean Williams

3 Cheap Growth Stocks You Can Buy Right Now

These are three cheap growth stocks, but they may not stay cheap for much longer.

Feb 12, 2015 by Sean Williams

5 Things GlaxoSmithKline PLC's Management Wants You to Know

GlaxoSmithKline's revenue fell 10% in the fourth quarter from the prior-year quarter, but this top-line figure doesn't give you the full story. However, this conference call with its management team sure does!

Feb 11, 2015 by Sean Williams

3 Cheap Dividend Stocks You Can Buy Right Now

These three cheap dividend stocks could put more money in your pocket, but they may not stay cheap for long.

Feb 11, 2015 by Sean Williams

Can You Bank on This Upgrade of Citigroup Inc.?

Are these returns you can bank on? According to the latest synopsis from Deutsche Bank it is, but call me not quite as convinced.

Feb 11, 2015 by Sean Williams

Does This Downgrade Signal That Gap Inc. Is Falling Out of Fashion?

Despite a stronger-than-expected end to fiscal 2014, Gap hits a snag in January and catches a downgrade from Mizuho Securities. Find out if this downgrade by Mizuho has any merit.

Feb 10, 2015 by Sean Williams

Is Apple Inc. Really Worth $145 Per Share?

Research firm Canaccord Genuity believes there could be more than 20% upside left in Apple's stock. Find out why the firm upped its price target yesterday and whether or not Apple could reach Canaccord's lofty target.

Feb 10, 2015 by Sean Williams

Could LinkedIn Corp. Actually Hit $300?

Following its blowout fourth-quarter earnings results, LinkedIn catches two additional price target increases. Find out whether or not LinkedIn has a chance at hitting Wall Street's lofty price targets.

Feb 10, 2015 by Sean Williams

Why Argus Gave Exxon Mobil Corporation Some Crude Treatment on Monday

Research firm Argus downgraded Exxon Mobil's stock on Monday and gave shareholders a crude awakening. Find out the impetus behind this downgrade and whether or not it has any merit.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services